Joseph Kwadwo Larbi Opare

Dr. Joseph Kwadwo Larbi Opare


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2021 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Closed access
JOJohn Kofi Odoom
John Kofi Odoom
EOEvangeline Obodai
Evangeline Obodai
GBGifty Boateng
Gifty Boateng
SDStanley Diamenu
Stanley Diamenu
KAKeren Attiku
Keren Attiku
JOJoseph Kwadwo Larbi Opare
Joseph Kwadwo Larbi Opare
On August 25, 2019, the Noguchi Memorial Institute for Medical Research notified the confirmation of a circulating-vaccine-derived poliovirus type-2 (cVDPV2) from the Agbogbloshie environmental sur...

23 September 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
PMPierre Muhoza
Pierre Muhoza
MSMonica P Shah
Monica P Shah
HGHongjiang Gao
Hongjiang Gao
KAKwame Amponsa-Achiano
Kwame Amponsa-Achiano
PQPamela Quaye
Pamela Quaye
Aaron WallaceAaron Wallace
Aaron Wallace
Background: Understanding the drivers of coverage for vaccines offered in the second year of life (2YL) is a critical focus area for Ghana’s life course approach to vaccination. This study characterizes the predictors of vaccine receipt for 2YL vaccines—meningococcal serogroup A conjugate vaccine (MACV) and the second dose of measles-containing vaccine (MCV2)—in Ghana. Methods: 1522 children aged 18–35 months were randomly sampled through household surveys in the Greater Accra Region (GAR), Northern Region (NR), and Volta Region (VR). The association between predictors and vaccination status was modeled using logistic regression with backwards elimination procedures. Predictors included child, caregiver, and household characteristics. Results: Coverage was high for infant vaccines (>85%) but lower for 2YL vaccines (ranging from 60.2% for MACV in GAR to 82.8% for MCV2 in VR). Predictors of vaccination status varied by region. Generally, older, first-born children, those living in rural settlements and those who received their recommended infant vaccines by their first birthday were the most likely to have received 2YL vaccines. Uptake was higher among those with older mothers and children whose caregivers were aware of the vaccination schedule. Conclusions: Improving infant immunization uptake through increased community awareness and targeted strategies, such as parental reminders about vaccination visits, may improve 2YL vaccination coverage.

6 June 2025 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
JOJoseph Kwadwo Larbi Opare
Joseph Kwadwo Larbi Opare
THTei Hervie
Tei Hervie
EMErnest Mensah
Ernest Mensah
CBCharles Brown-Davies
Charles Brown-Davies
OAOdame Asiedu
Odame Asiedu
APAnna Elizabeth Phillips
Anna Elizabeth Phillips
Background: Schistosomiasis is a major public health problem in Ghana, significantly impacted by the construction of dams during the 1960s that resulted in the creation of Lake Volta. The Ghana Health Service launched the Neglected Tropical Disease program in 2008, expanding baseline disease mapping first initiated in 2007 to additional geographic areas in 2008 and 2010 and simultaneously rolling out mass drug administration (MDA). Significant reduction of infection across the country was noted in 2015 during the first impact assessment, following five years of MDA. After another five years of treatment, a second nationwide survey has been rolled out since 2021 to re-evaluate the situation of schistosomiasis this time at the sub-district level.Methods: Prevalence at three time points is presented. At baseline (2007–2010), a cross-section of 13,299 school-aged children (SAC) were tested from 251 schools across 154 districts in Ghana. During the first impact assessment (2015), 156 schools were sampled across 114 districts, with a total of 7,803 SAC tested. More recently, a second impact evaluation (2021-2024) has been rolled out across 1,146 schools sampled in 61 districts, with a total, 29,924 SAC tested. In all surveys, urine samples were filtered for the presence of Schistosoma haematobium eggs, with haemastix® testing conducted in recent surveys only, and Kato-Katz performed on each stool sample for the presence of Schistosoma mansoni.Results: At baseline, overall schistosomiasis prevalence was 21.1% (95% CI 17.0–26.0), with 20.4% (95% CI 16.4–25.2) S.haematobium and 1.01% (95% CI 0.55–1.84) S.mansoni. Prevalence of schistosomiasis decreased dramatically at first impact assessment, with overall prevalence at 3.5% (95% CI 2.6–4.7) and remained low in recent surveys at 6.8% (95% CI 6.1–7.6), which represents a 67.8% reduction from baseline to current prevalence.Conclusion: After over a decade of treatment since 2008, Ghana has made significant progress in reducing the burden of schistosomiasis infection. Indeed, the most recent surveys demonstrated that elimination as a public health problem (heavy intensity of infection <1%) has been achieved in 75.4% districts surveyed, which is a considerable achievement. Furthermore, recent assessments have been conducted at the sub-district level, which has therefore enabled the Ghana Health Service to change to a more focal intervention and therefore tackle morbidity in the remaining high transmission zones.

26 June 2019 in Ghana Medical Journal
Verified
Journal Article
Open access
PDF file
JOJoseph Kwadwo Larbi Opare
Joseph Kwadwo Larbi Opare
PAPatricia Akweongo
Patricia Akweongo
EAEdwin A. Afari
Edwin A. Afari
JOJohn K. Odoom
John K. Odoom
Poliovirus neutralizing antibody levels among individuals in three regions of Ghana

Verified
Journal Article
Open access
PDF file
ASAhorlu Collins Stephen
Ahorlu Collins Stephen
JOJoseph Otchere
Joseph Otchere
KSKojo M. Sedzro
Kojo M. Sedzro
SPSellase Pi-Bansa
Sellase Pi-Bansa
KAKofi Asemanyi-Mensah
Kofi Asemanyi-Mensah
DSDziedzom De Souza
Dziedzom De Souza
Background: Ghana joined the Global Programme to Eliminate Lymphatic Filariasis (GPELF), established in the year 2000, with the aim of eliminating the disease as a public health problem through annual mass treatment of entire endemic populations. Since 2001, the country has implemented mass drug administration (MDA) in endemic districts, with great reductions in the population at risk for infection. However, in many districts, the elimination programme is faced with the presence of hotspots, which may be due in part to individuals not taking part in MDA (either intentionally or unintentionally) who may serve as reservoirs to sustain transmission. This paper compares the LF-related perceptions among individuals who regularly take the MDA drugs and those who seldom or never take part in the MDA in the Ahanta West Municipality of Ghana to determine community acceptable ways to implement an intervention aimed to track, engage, and treat individuals who regularly miss MDA or to test individuals who intentionally refuse MDA and treat them if positive for LF. Methods: This was a mixed method study employing questionnaire surveys and focus group discussions (FDG) for data collection. Survey participants were randomly selected from the 2019 treatment register to stratify respondents into treated and non-treated groups. FGD participants were selected purposively such that there are at least two non-treated persons in each discussion session. Results: Over 90% of the respondents were aware of the disease. Poor hygiene/dirty environment was wrongly reported by most respondents (76.8%) as the causes. MDA awareness was very high among both treated (96.9%) and non-treated (98.6%) groups. A low sense of vulnerability to LF infection was evident by a reduction in the number of people presenting clinical manifestations of the disease in communities. Slightly more, 65 (29.0%) of the non-treated group compared to the 42 (19.4%) treated group reported ever experiencing adverse effects of the MDA drugs. Barriers to MDA uptake reported in both groups were poor planning and implementation of the MDA, lack of commitments on the part of drug distributors, and adverse drug reactions. About 51% of the non-treated group reported never taking the drugs even once in the last five years, while 61% among the treated group took the MDA drug consistently in the past five years. Respondents in both groups believed that, when engaged properly, most non-treated persons will accept to take the drug but insisted community drug distributors (CDDs) must be trained to effectively engage people and have time for those they will be engaging in dialogue. The chiefs emerged as the most influential people who can influence people to take MDA drugs. Conclusions: The reduction in risk perception among respondents, adverse reactions and the timing of MDA activities may be influencing MDA non-participation in the study area; however, respondents think that non-treated individuals will accept the interventions when engaged properly by the CDDs.

27 June 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
PMPierre Muhoza
Pierre Muhoza
MSMonica P Shah
Monica P Shah
KAKwame Amponsa-Achiano
Kwame Amponsa-Achiano
HGHongjiang Gao
Hongjiang Gao
PQPamela Quaye
Pamela Quaye
AWAaron S. Wallace
Aaron S. Wallace
Strengthening routine immunization systems to successfully deliver childhood vaccines during the second year of life (2YL) is critical for vaccine-preventable disease control. In Ghana, the 18-month visit provides opportunities to deliver the second dose of the measles–rubella vaccine (MR2) and for healthcare workers to assess for and provide children with any missed vaccine doses. In 2016, the Ghana Health Service (GHS) revised its national immunization policies to include guidelines for catch-up vaccinations. This study assessed the change in the timely receipt of vaccinations per Ghana’s Expanded Program on Immunizations (EPI) schedule, an important indicator of service quality, following the introduction of the catch-up policy and implementation of a multifaceted intervention package. Vaccination coverage was assessed from household surveys conducted in the Greater Accra, Northern, and Volta regions for 392 and 931 children aged 24–35 months with documented immunization history in 2016 and 2020, respectively. Age at receipt of childhood vaccines was compared to the recommended age, as per the EPI schedule. Cumulative days under-vaccinated during the first 24 months of life for each recommended dose were assessed. Multivariable Cox regression was used to assess the associations between child and caregiver characteristics and time to MR2 vaccination. From 2016 to 2020, the proportion of children receiving all recommended doses on schedule generally improved, the duration of under-vaccination was shortened for most doses, and higher coverage rates were achieved at earlier ages for the MR series. More timely infant doses and caregiver awareness of the 2YL visit were positively associated with MR2 vaccination. Fostering a well-supported cadre of vaccinators, building community demand for 2YL vaccination, sustaining service utilization through strengthened defaulter tracking and caregiver-reminder systems, and creating a favorable policy environment that promotes vaccination over the life course are critical to improving the timeliness of childhood vaccinations.